Redeye believes Q2 was quite eventful for InDex Pharmaceuticals, with the highlight being a USD50m d...
Redeye provides a brief comment on Sprint Bioscience’s Q2 report.
Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum.
Redeye raises its base case following a case review of OssDsign and we positively reconsider its com...
Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX...
Weak sales in both segments but better gross margin.
Vow's H1 results showed encouraging performance in both the Maritime and Aftersales divisions; howev...
Redeye updates its view on Artificial Solutions on the back its Q2 2023 report, where ARR and recurr...
Earnings forecast lowered by 5-25% Q2'23e sales increase of 7% Focus on the ongoing stategic process...
Zoomability publicerade den 23 augusti 2023 bolagets delårsrapport för årets andra kvartal.
Redeye comments on AVTECHs announcement where it upsold Aventus Wind Services to Volotea.
Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e...
Recyctec publicerade den 22 augusti år 2023 bolagets delårsrapport för det andra kvartalet.
148% tillväxt i USA. OssDsigns nettoomsättning under Q2 uppgick till 24 mkr vilket motsvarar 92% til...
Inga överraskningar i rapporten Egetis rapport för det andra kvartalet var i linje med våra förväntn...
Redeye leaves its comments on Ortoma following its Q2 2023 report.
Redeye comments on Enviro’s Q2 2023 report, which held no surprises – as expected.
Redeye leaves a comment following Newbury’s announcement of a new strategic partnership with a globa...
Redeye comments the quarter was weaker than expected.
Redeye states that Modelon’s financial performance was above our projections on sales and profitabil...
